From: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Phase | Disease (pt. No.) | Schedule | Recommended dose & response | Reference |
---|---|---|---|---|
I | Relapsed or refractory AML (15), MDS (1) and ALL(1). | Day 1 to 7 of a 21-day cycle | 11.5 mg/m2 | [108] |
I | Cutaneous T-cell lymphoma(9) | Monday, Wednesday and Friday of each week on a 28-day cycle | 20 mg a day, CR 22.2%, PR 44.4%, SD 11.1%, POD 22.2% | [105] |
I | Castration-resistant prostate cancer (16) | Arm I: 20 mg on 1,3 and 5 for 2 weeks on a 28-day cycle; Arm II: 15 mg on 1,3 and 5 for 2 weeks on a 28-day cycle with docetaxel and prednisone | Arm I: POD 100%; arm II: PR 37.5% | [112] |
II | Advanced CTCL(stage IB-IVA) Group 1 previously treated with bexarotene(25); group 2 bexarotene naïve(15) | Days 1,3, and 5 weekly until disease progression or intolerance | Group 1: PR12%, SD16%, PD12%;other patients and most patients in groups have had less than 2 months of follow-up. | [109] |